Yano K, Fukuda Y, Sumimoto R, Sumimoto K, Ito H, Dohi K
Second Department of Surgery, School of Medicine, Hiroshima University, Japan.
Transpl Int. 1994 May;7(3):149-56.
In this experiment, the effect of the administration route-the hepatic artery, portal vein, or systemic circulation-of the immunosuppressive drug 15-deoxyspergualin (DSG) on the suppression of liver allograft rejection is investigated. A 3-day injection of DSG at a dose of 0.32-1.28 mg/kg per day into the systemic circulation of a rat that had received a liver transplant was not effective in prolonging liver graft survival (14.3 +/- 2.9 days vs. 14.1 +/- 2.5 days for controls). However, the administration of DSG into the portal vein following liver transplantation markedly prolonged survival for up to 24.9 +/- 10.0 days. Survival times were prolonged even more when the DSG was administered via the hepatic artery for 3 successive days after liver grafting (30.9 +/- 9.6 days). The concentration of DSG in the blood following the one-shot injection of DSG was highest when DSG was administered via the hepatic artery, intermediate when injected into the portal vein, and lowest when injected into the systemic vein. In conclusion, DSG can inhibit liver graft rejection more effectively via the hepatic arterial route than via the portal vein or systemic circulation.
在本实验中，研究了免疫抑制药物15-脱氧精胍菌素（DSG）的给药途径（肝动脉、门静脉或体循环）对抑制肝移植排斥反应的影响。对接受肝移植的大鼠进行为期3天的DSG注射，剂量为每天0.32-1.28mg/kg，经体循环给药对延长肝移植存活期无效（对照组为14.3±2.9天，给药组为14.1±2.5天）。然而，肝移植后经门静脉给予DSG可显著延长存活期，长达24.9±10.0天。肝移植后连续3天经肝动脉给予DSG，存活时间延长得更多（30.9±9.6天）。单次注射DSG后，经肝动脉给药时血液中DSG浓度最高，经门静脉注射时浓度中等，经体静脉注射时浓度最低。总之，DSG通过肝动脉途径比通过门静脉或体循环能更有效地抑制肝移植排斥反应。
